1. Home
  2. AKTX vs MOBX Comparison

AKTX vs MOBX Comparison

Compare AKTX & MOBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$7.18

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

Logo Mobix Labs Inc.

MOBX

Mobix Labs Inc.

SELL

Current Price

$1.72

Market Cap

13.6M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
AKTX
MOBX
Founded
N/A
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
13.6M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKTX
MOBX
Price
$7.18
$1.72
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.50
N/A
AVG Volume (30 Days)
32.2K
★ 700.0K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $6,442,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 426.31
52 Week Low
$0.12
$0.13
52 Week High
$29.32
$4.25

Technical Indicators

Market Signals
Indicator
AKTX
MOBX
Relative Strength Index (RSI) 42.25 63.10
Support Level $5.01 $1.74
Resistance Level $9.91 $2.16
Average True Range (ATR) 0.90 0.18
MACD -0.06 0.16
Stochastic Oscillator 24.25 55.16

Price Performance

Historical Comparison
AKTX
MOBX

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About MOBX Mobix Labs Inc.

Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.

Share on Social Networks: